Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
CellSource Co., Ltd. ( (JP:4880) ) just unveiled an announcement.
CellSource Co., Ltd. has announced an absorption-type company split involving its subsidiary, Medibase Co., Ltd., and GMO Beauty Co., Ltd. This strategic move is part of CellSource’s long-term vision to enhance its orthopedic services and retain key human resources within the group. The split will allow GMO Beauty to take over Medibase’s business assets and obligations, with the transaction valued at 300 million yen. This restructuring aims to accelerate CellSource’s growth and align with its business objectives.
More about CellSource Co., Ltd.
CellSource Co., Ltd. operates in the medical industry, focusing on developing services for affiliated medical institutions and patient-oriented services in the orthopedic field. The company aims to eliminate knee pain and has acquired Medibase Co., Ltd. to incorporate its technology and expertise.
YTD Price Performance: -2.64%
Average Trading Volume: 92,660
Technical Sentiment Consensus Rating: Buy
Current Market Cap: Yen16.05B
See more insights into 4880 stock on TipRanks’ Stock Analysis page.